Wai Wai Lin, MD
Endocrinology, Diabetes & Metabolism · Dover, DENPI 1033513619
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $615 of the $762 with a category attached, or 80.7%. It is spread thinly across 14 manufacturers, the largest accounting for just 23.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $459, 4.8 times the $96 reported in 2019. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in DE, where the typical reported total is $1,261.
Across 26 payments — averaging $29.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$178
- Novo Nordisk$102
- Medtronic$96
- Mannkind Corporation$93
- Lilly USA, LLC$92
- Ascendis Pharma Endocrinology Inc$36
- plus $164 from 8 others
What the payments were for
- Food & beverage$61581%
- Education$14719%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 1 | $178 |
| Novo Nordisk | 5 | $102 |
| Medtronic | 2 | $96 |
| Mannkind Corporation | 3 | $93 |
| Lilly USA, LLC | 5 | $92 |
| Ascendis Pharma Endocrinology Inc | 2 | $36 |
| BETA Bionics, Inc. | 1 | $32 |
| United Therapeutics Corporation | 1 | $24 |
| Abbott | 1 | $22 |
| Averitas Pharma Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Recordati_rare_diseases_inc. | 1 | $17 |
| Corcept Therapeutics | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$178
How this compares
$762 in reported general payments places this provider in the 40th percentile of 30 endocrinology, diabetes & metabolism providers in Delaware.
See all endocrinology, diabetes & metabolism providers in Delaware →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 125 | $191,597 |
| TrulicityDulaglutide | 64 | $85,316 |
| JardianceEmpagliflozin | 41 | $54,547 |
| MounjaroTirzepatide | 29 | $39,148 |
| FarxigaDapagliflozin Propanediol | 12 | $16,652 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 84 | $14,032 |
| Humalog Kwikpen U-100Insulin Lispro | 36 | $12,273 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 23 | $2,932 |
| SynthroidLevothyroxine Sodium | 21 | $2,183 |
| Levothyroxine Sodium | 60 | $658 |
| Metformin Hcl ErMetformin Hcl | 38 | $453 |
| Glipizide | 13 | $343 |
| Metformin Hcl | 29 | $262 |
| Pioglitazone Hcl | 16 | $152 |
| Rosuvastatin Calcium | 14 | $97 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $102 | $191,597125 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $92 | $124,46593 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 30 endocrinology, diabetes & metabolism providers in Delaware.
Other endocrinology, diabetes & metabolism in Dover
- Chitra ChoudharyDover$5K
- Manveen DuggalDover$2K
- Hira ShakeelDover$240
- Hajira AmirDover$187
- Hasitha VemulaDover$96
- Ripudaman HundalNewark$370K
- Nira MadisiMilford$23K
- Francisco PadillaSeaford$22K
- Reetu SinghLewes$9K
- Joanna KhatibMillsboro$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.